Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DX-890 (Dyax).

Peter A B Wark1

  • 1Southampton General Hospital, RCMB Research Division, Tremona Road, Southampton, SO16 6YD, UK. p.wark@soton.ac.uk

Idrugs : the Investigational Drugs Journal
|June 13, 2003
PubMed
Summary
This summary is machine-generated.

DX-890, an inhibitor of human neutrophil elastase (HNE), is being developed for pulmonary diseases like cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Clinical trials are underway to evaluate its potential as a novel therapeutic agent.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sustained clinical remission and relapse of severe eosinophilic asthma following long-term mepolizumab treatment.

Allergology international : official journal of the Japanese Society of Allergology·2026
Same author

ORIGIN-1 trial: study protocol for an organoid-guided N-of-1 trial evaluating CFTR modulator response in cystic fibrosis with rare non-F508del mutations.

Trials·2026
Same author

Impaired mucociliary clearance in bronchiectasis: the result of a differentiation-delayed airway epithelium?

American journal of physiology. Lung cellular and molecular physiology·2026
Same author

Resolving Endoplasmic Reticulum-Protein Misfolding Restores Corticosteroid Sensitivity in Experimental Models of Severe Asthma.

Allergy·2026
Same author

When Neutrophils Go Rogue: Dysregulated Inflammation in Airway Diseases and Implications for Therapy.

ACS pharmacology & translational science·2026
Same author

Pilot investigation of an oligosaccharide blend in adults with asthma - a double-blind, randomised, placebo-controlled, 4-arm crossover trial.

Respiratory medicine·2025
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Area of Science:

  • Pharmacology
  • Pulmonary Medicine
  • Drug Development

Background:

  • Human neutrophil elastase (HNE) plays a role in the pathogenesis of pulmonary diseases.
  • Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD) are significant respiratory conditions with unmet treatment needs.

Purpose of the Study:

  • To evaluate DX-890, a novel HNE inhibitor, for the potential treatment of pulmonary diseases.
  • To assess the safety and efficacy of DX-890 in patients with CF and COPD.

Main Methods:

  • Phase I trials of an aerosol formulation of DX-890 were initiated in December 1999 and completed by October 2000.
  • Phase II trials for CF treatment were initiated by August 2000, with ongoing studies in France and Spain by June 2002.
  • Further studies in children with CF were planned for initiation within 2002.

Related Experiment Videos

Main Results:

  • Phase I studies were completed, providing initial safety data.
  • Phase II trials for CF were ongoing, with results anticipated shortly after June 2002.
  • Financial projections indicated a potential 2005 launch with significant sales forecasts.

Conclusions:

  • DX-890 shows promise as a potential treatment for CF and COPD.
  • Ongoing clinical trials are crucial for determining the drug's therapeutic value.
  • The development of DX-890 represents a significant effort in addressing pulmonary disease treatment.